Investigator
Associate Professor · National University of Singapore, Dept of Medicine, Yong Loo Lin School of Medicine
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
The primary purpose is to assess the safety and tolerability of tilvestamab following IV administration of multiple doses to participants with HGSOC who have been treated with at least 1 complete course of platinum-based chemotherapy and whose disease has relapsed with platinum resistance (\[PRR\]-HGSOC) and to determine the plasma pharmacokinetics (PK) exposure by comprehensive profiling (at single dose and steady-state) of multiple ascending doses of tilvestamab.
Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer
This study is phase II, open label, clinical trial to determine the efficacy of Olaparib maintenance with Bevacizumab and Pembrolizumab by assessment progression-free survival(6 months PFS rate) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer.
Associate Professor
National University of Singapore · Dept of Medicine, Yong Loo Lin School of Medicine
Principal Investigator
National University of Singapore · Cancer Science Institute
Senior Consultant
National University Cancer Institute · Medical Oncology
Fellow
Princess Margaret Cancer Centre · Gynecologic Medical Oncology and Drug Development
Registrar
Royal Marsden Hospital · Medical Oncology
Cancer Research UK PhD Fellowship
The Institute of Cancer Research
SG